company background image
SCLP logo

Scancell Holdings AIM:SCLP Stock Report

Last Price

UK£0.14

Market Cap

UK£130.1m

7D

4.7%

1Y

17.9%

Updated

12 Nov, 2024

Data

Company Financials +

SCLP Stock Overview

A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.

SCLP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Scancell Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Scancell Holdings
Historical stock prices
Current Share PriceUK£0.14
52 Week HighUK£0.20
52 Week LowUK£0.086
Beta0.45
11 Month Change5.66%
3 Month Change-26.32%
1 Year Change17.89%
33 Year Change-30.00%
5 Year Change177.23%
Change since IPO359.02%

Recent News & Updates

Recent updates

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Oct 29
Is Scancell Holdings (LON:SCLP) A Risky Investment?

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Feb 10
Is Scancell Holdings (LON:SCLP) A Risky Investment?

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Dec 28
Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Shareholder Returns

SCLPGB BiotechsGB Market
7D4.7%-1.9%-1.8%
1Y17.9%-18.4%5.8%

Return vs Industry: SCLP exceeded the UK Biotechs industry which returned -15.2% over the past year.

Return vs Market: SCLP exceeded the UK Market which returned 7.9% over the past year.

Price Volatility

Is SCLP's price volatile compared to industry and market?
SCLP volatility
SCLP Average Weekly Movement6.9%
Biotechs Industry Average Movement8.7%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.0%
10% least volatile stocks in GB Market2.6%

Stable Share Price: SCLP's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: SCLP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
199761Linda Durrantwww.scancell.co.uk

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.

Scancell Holdings plc Fundamentals Summary

How do Scancell Holdings's earnings and revenue compare to its market cap?
SCLP fundamental statistics
Market capUK£130.14m
Earnings (TTM)-UK£5.86m
Revenue (TTM)n/a

0.0x

P/S Ratio

-22.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCLP income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£5.86m
Earnings-UK£5.86m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0063
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-541.3%

How did SCLP perform over the long term?

See historical performance and comparison